Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response

Trial Profile

Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Aldesleukin (Primary)
  • Indications Malignant melanoma; Renal cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms IL2HD
  • Most Recent Events

    • 11 Jan 2018 Planned number of patients changed from 19 to 35.
    • 11 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2019.
    • 11 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top